Your browser doesn't support javascript.
loading
MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs.
Pyzer, A R; Stroopinsky, D; Rosenblatt, J; Anastasiadou, E; Rajabi, H; Washington, A; Tagde, A; Chu, J-H; Coll, M; Jiao, A L; Tsai, L T; Tenen, D E; Cole, L; Palmer, K; Ephraim, A; Leaf, R K; Nahas, M; Apel, A; Bar-Natan, M; Jain, S; McMasters, M; Mendez, L; Arnason, J; Raby, B A; Slack, F; Kufe, D; Avigan, D.
Afiliação
  • Pyzer AR; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Stroopinsky D; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Rosenblatt J; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Anastasiadou E; Department of Pathology, Institute for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Rajabi H; Department of Medical Oncology, Dana Farber Cancer Institute, Medical Oncology, Harvard Medical School, Boston, MA, USA.
  • Washington A; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Tagde A; Department of Medical Oncology, Dana Farber Cancer Institute, Medical Oncology, Harvard Medical School, Boston, MA, USA.
  • Chu JH; Section of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
  • Coll M; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Jiao AL; Department of Pathology, Institute for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Tsai LT; Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Tenen DE; Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Cole L; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Palmer K; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Ephraim A; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Leaf RK; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Nahas M; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Apel A; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Bar-Natan M; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Jain S; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • McMasters M; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Mendez L; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Arnason J; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
  • Raby BA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Slack F; Department of Pathology, Institute for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Kufe D; Department of Medical Oncology, Dana Farber Cancer Institute, Medical Oncology, Harvard Medical School, Boston, MA, USA.
  • Avigan D; Department of Medicine, Beth Israel Deaconess Medical Center, Hematology/Oncology, Harvard Medical School, Boston, MA, USA.
Leukemia ; 31(12): 2780-2790, 2017 12.
Article em En | MEDLINE | ID: mdl-28555079
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Regulação Leucêmica da Expressão Gênica / Mucina-1 / MicroRNAs / Antígeno B7-H1 Idioma: En Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Regulação Leucêmica da Expressão Gênica / Mucina-1 / MicroRNAs / Antígeno B7-H1 Idioma: En Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos